Biodesix Inc (NAS:BDSX)

$ 1.55 -0.1 (-6.06%) Market Cap: 177.76 Mil Enterprise Value: 240.06 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 55/100

Q1 2024 Biodesix Inc Earnings Call Transcript
May 08, 2024

$1.55

Earnings
Q4 2023 Biodesix Inc Earnings Call Transcript
Mar 01, 2024

$1.58 (+2.60%)

Earnings
Q3 2023 Biodesix Inc Earnings Call Transcript
Nov 07, 2023

$1.48 (+2.07%)

Earnings
Biodesix Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Biodesix Inc at Canaccord Genuity Growth Conference Transcript
Aug 09, 2023
Q2 2023 Biodesix Inc Earnings Call Transcript
Aug 07, 2023

$1.54 (-2.53%)

Earnings
Biodesix Inc at William Blair Growth Stock Conference Transcript
Jun 07, 2023
Q1 2023 Biodesix Inc Earnings Call Transcript
May 11, 2023

$1.71 (+4.27%)

Earnings
Biodesix Inc at Cowen Health Care Conference Transcript
Mar 07, 2023
Q4 2022 Biodesix Inc Earnings Call Transcript
Mar 06, 2023

$1.8 (-10.00%)

Earnings
Q3 2022 Biodesix Inc Earnings Call Transcript
Nov 03, 2022

$1.05 (+2.75%)

Earnings
Biodesix Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Biodesix Inc at Canaccord Genuity Growth Conference Transcript
Aug 10, 2022
Q2 2022 Biodesix Inc Earnings Call Transcript
Aug 04, 2022

$2.89 (+4.71%)

Earnings
Biodesix Inc at William Blair Growth Stock Conference Transcript
Jun 08, 2022
Q1 2022 Biodesix Inc Earnings Call Transcript
May 11, 2022

$1.51 (-15.41%)

Earnings
Q4 2021 Biodesix Inc Earnings Call Transcript
Mar 14, 2022

$2.16 (-3.57%)

Earnings
Q3 2021 Biodesix Inc Earnings Call Transcript
Nov 15, 2021

$7.69 (-1.54%)

Earnings
Q2 2021 Biodesix Inc Earnings Call Transcript
Aug 10, 2021

$9.84 (+7.42%)

Earnings
Q1 2021 Biodesix Inc Earnings Call Transcript
May 11, 2021

$14.75 (-1.73%)

Earnings

Biodesix Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 01:10PM GMT

Release Date Price: $1.67 (-3.47%)

Transcript

Yuko Oku

Morgan Stanley & Co LLC - Analyst

Hi. My name is Yuko Oku, and I'm on the life science tools and diagnostics team here at MS. Before we begin, I would like to remind our listeners that important disclosure information can be found at morganstanley.com/researchdisclosures. It's my pleasure to host Biodesix. And on behalf of the company, the CEO, Scott Hutton, thank you for joining us today.

Scott Hutton

Biodesix, Inc. - President, CEO & Director

Yeah, thank you.

Questions & Answers

Yuko Oku

Morgan Stanley & Co LLC - Analyst

Maybe to start, could you begin by highlighting some of Biodesix's key accomplishments this year and what you're most excited about as we head into '23?

Scott Hutton

Biodesix, Inc. - President, CEO & Director

Yeah, it's a great question. 2022 has been a big year for us as we come out of COVID. Physicians returning to practice was key for us, right, focusing on the pulmonology call point. We know pulmonologists

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.